文献速递肿瘤 PET/CT放射性药物与辐射防护

99mTc标记抗PD-L1单域抗体SPECT/CT评估非小细胞肺癌PD-L1表达的早期I期研究

Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer.
PubMed 文献 · J Nucl Med · 2019-02-22

结果显示无药物相关不良事件,平均有效剂量为8.84×10-3±9.33×10-4 mSv/MBq(每例患者3.59±0.74 mSv),2小时原发肿瘤与血池比值(T:BP)与PD-L1免疫组化结果相关(r=0.68,P=0.014)。

要点

  • 99mTc-NM-01 SPECT/CT成像安全,无药物相关不良事件,辐射剂量可接受。
  • 2小时T:BP与PD-L1免疫组化相关(r=0.68,P=0.014),≤1%表达者T:BP较低。
  • 可显示淋巴结和骨转移灶的示踪剂摄取,并发现原发灶与淋巴结间异质性。

核心结论

  • 99mTc标记抗PD-L1单域抗体SPECT/CT成像安全且剂量学可接受,2小时肿瘤摄取与PD-L1免疫组化结果相关。

研究设计与样本

  • NM-01经位点特异性99mTc标记,给药活度为3.8-10.4 MBq/kg,对应100 μg或400 μg NM-01。
  • 所有患者于注射后1和2小时行全身平面及胸部SPECT/CT,其中5例额外在10分钟、3小时和24小时成像用于剂量学计算。

主要发现

  • 研究中无药物相关不良事件发生。
  • 平均有效剂量为8.84×10-3±9.33×10-4 mSv/MBq(每例患者3.59±0.74 mSv)。
  • 示踪剂摄取见于肾脏、脾脏、肝脏和骨髓。
  • SPECT原发肿瘤与血池比值(T:BP)在1小时为1.24至2.3(均值1.79),2小时为1.24至3.53(均值2.22),P=0.005。
  • 2小时原发肿瘤T:BP与PD-L1免疫组化结果相关(r=0.68,P=0.014),且PD-L1表达≤1%的肿瘤2小时T:BP较低(1.89 vs. 2.49,P=0.048)。

关键数值与推荐

  • 2小时原发肿瘤T:BP与PD-L1免疫组化结果相关(r=0.68,P=0.014)。
  • PD-L1表达≤1%的肿瘤2小时T:BP较低(1.89 vs. 2.49,P=0.048)。
  • 原发肿瘤与淋巴结间T:BP异质性>20%见于4/13例患者。

临床怎么用

  • 99mTc-NM-01 SPECT/CT可用于无创评估非小细胞肺癌PD-L1表达状态,2小时成像时T:BP与免疫组化结果相关性较好。
  • 该成像可显示淋巴结和骨转移灶摄取,并揭示原发灶与转移灶间的PD-L1表达异质性。

局限性

  • 仅5例患者进行了额外时间点成像用于剂量学计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced non-small cell lung cancer. Treatment stratification depends on immunohistochemical PD-L1 measurement of biopsy material, an invasive method that does not account for spatiotemporal heterogeneity. Using a single-domain antibody, NM-01, against PD-L1, radiolabeled site-specifically with 99mTc for SPECT imaging, we aimed to assess the safety, radiation dosimetry, and imaging characteristics of this radiopharmaceutical and correlate tumor uptake with PD-L1 immunohistochemistry results. Methods: Sixteen patients (mean age, 61.7 y; 11 men) with non-small cell lung cancer were recruited. Primary tumor PD-L1 expression was measured by immunohistochemistry. NM-01 was radiolabeled with [99mTc(OH2)3(CO)3]+ complex binding to its C-terminal hexahistidine tag. Administered activity was 3.8-10.4 MBq/kg, corresponding to 100 μg or 400 μg of NM-01. Whole-body planar and thoracic SPECT/CT scans were obtained at 1 and 2 h after injection in all patients, and 5 patients underwent additional imaging at 10 min, 3 h, and 24 h for radiation dosimetry calculations. All patients were monitored for adverse events. Results: No drug-related adverse events occurred in this study. The mean effective dose was 8.84 × 10-3 ± 9.33 × 10-4 mSv/MBq (3.59 ± 0.74 mSv per patient). Tracer uptake was observed in the kidneys, spleen, liver, and bone marrow. SPECT primary tumor-to-blood-pool ratios (T:BP) varied from 1.24 to 2.3 (mean, 1.79) at 1 h and 1.24 to 3.53 (mean, 2.22) at 2 h (P = 0.005). Two-hour primary T:BP ratios correlated with PD-L1 immunohistochemistry results (r = 0.68, P = 0.014). Two-hour T:BP was lower in tumors with ≤1% PD-L1 expression (1.89 vs. 2.49, P = 0.048). Nodal and bone metastases showed tracer uptake. Heterogeneity (>20%) between primary tumor and nodal T:BP was present in 4 of 13 patients. Conclusion: This first-in-human study demonstrates that 99mTc-labeled anti-PD-L1-single-domain antibody SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2 h when the T:BP ratio correlates with PD-L1 immunohistochemistry results.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xing Y, Chand G, Liu C, et al. Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. J Nucl Med. 2019. PMID: 30796165. doi:10.2967/jnumed.118.224170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。